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Table 1. Univariable Hazard Ratios of CKD With 95% Conﬁdence
Intervals
Factor
No CKD
(n  1314)
CKD
(n  279)
Hazard Ratio
(95% CI)
Age (years)
0–10 176 (95) 10 (5) 0.2 (0.1–0.5)
11–17 81 (81) 19 (19) 0.9 (0.6–1.5)
18–40 474 (82) 106 (18) 0.9 (0.7–1.2)
>40 583 (80) 144 (20) 1.0
Sex
Female 626 (81) 143 (19) 1.0
Male 688 (83) 136 (17) 0.9 (0.7–1.1)
Donor
Matched sibling 537 (82) 117 (18) 1.0
Non-sibling
relative
79 (77) 24 (23) 1.4 (0.9–2.2)
Unrelated 425 (77) 128 (23) 1.4 (1.1–1.8)
Autologous or id
twin
273 (96) 10 (4) 0.2 (0.1–0.4)
Transplant type
Non-myeloablative 56 (77) 17 (23) 1.0
Myeloablative 1258 (83) 262 (17) 1.4 (0.9–2.3)
TBI Conditioning
No 569 (87) 83 (13) 1.0
Yes 745 (79) 196 (21) 1.7 (1.3–2.2)
Cyclosporine
prophylaxis
No 79 (89) 10 (11) 1.0
Yes 990 (79) 261 (21) 1.9 (1.0–3.5)
Missing 245 (97) 8 (3) 0.3 (0.1–0.7)
Bilirubin in first 100
days
Median (range)
Average 1.1 (0.2–16.5) 1.7 (0.2–16.4) 1.2 (1.16–1.25)
Maximum 2.4 (0.2–41.2) 4.0 (0.3–56.8) 1.07 (1.05–1.08)
Acute GVHD grade
0 143 (88) 19 (12) 1.0
I 64 (94) 4 (6) 0.5 (0.2–1.5)
II 576 (83) 115 (17) 1.5 (0.9–2.4)
III or IV 249 (66) 127 (34) 3.7 (2.3–5.9)
Auto or twin 273 (96) 10 (4) 0.3 (0.1–0.7)
Chronic GVHD
No 369 (73) 136 (27) 1.0
Yes 643 (84) 123 (16) 1.8 (1.4–2.3)
Auto or twin
transplant
273 (96) 10 (4) 0.2 (0.1–0.4)
Missing 29 (74) 10 (26) 2.3 (1.2–4.3)
ARF before day 60
No 1050 (85) 187 (15) 1.0
Yes 264 (74) 92 (26) 1.8 (1.4–2.4)
Diagnosis
ALL 151 (86) 24 (14) NS/data not
shown
ANL 236 (79) 64 (21) NS
CML 383 (79) 99 (21) NS
MDS 147 (77) 44 (23) NS
MM 62 (83) 13 (17) NS
NHL 95 (87) 14 (13) NS
Other 240 (92) 21 (8) NS
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JC VIRUS REACTIVATION IN HEMORRHAGIC CYSTITIS COMPLICATING
BONE MARROW TRANSPLANTATION PATIENTS
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Molecular Diagnostic Research, ViraCor Laboratories, Lee’s Summit,
MO; 2St. Joseph Regional Medical Center, Patterson, NJ.
Background: Late-onset hemorrhagic cystitis (HC) is a well-
known severe complication of bone marrow transplantation
(BMT). Protracted postengraftment HC is associated with graft-
versus-host disease and viral infections, caused mainly by BK virus
(BKV) or adenoviruses (AdV). However, the roles of other closely
related polyomaviruses, such as JCV and SV40, are not known.
Here we investigated whether these polyomaviruses can also be
detected in patients affected by postengraftment HC. Methods:
We screened 47 blood specimens obtained from 27 BMT patients
affected by HC to diagnose for JCV, BKV, and adenovirus infec-
tions. We also screened for herpesviruses, such as EBV and CMV,
on these patients to determine their roles in clinical complications
of HC. Results: We have developed quantitative real-time PCR
assays that are highly sensitive and speciﬁc for each virus. Our
results showed that although the majority of the patients (15 of 27
patients; 55%) with HC were diagnosed to have BK infections;
JCV was detected in 2 patients (7%). BKV viruria was also detected
in these 2 JCV-positive patients affected by postengraftment HC.
Adenoviruses, the other pathogens that also cause HC, were de-
tected in 2 patients (7%). One patient (3%) had both BKV and
JCV coinfections. Additionally, 8 patients (30%) were simulta-
neously infected with herpesviruses and polyomaviruses, compared
with herpesviruses alone (4 patients or 15%). SV40 was not de-
tected in any of these patients. Conclusions: A large proportion of
the BMT patients suffering from HC are diagnosed to have poly-
omaviruses. The detection of JC virus suggests that this virus may
be involved in the HC in BMT patients. Polyomaviruses share
substantial structural and genomic sequence homologies; however,
their clinical manifestations differ signiﬁcantly. These viruses es-
tablish subclinical and persistent infections and share the capacity
for reactivation from latency in their host under immunosuppres-
sion. JCV establishes latency mainly in the kidney, and its reacti-
vation results in the development of progressive multifocal leu-
koencephalopathy. BKV causes infection in the kidney and the
urinary tract, and its activation causes a number of disorders,
including nephropathy and hemorrhagic cystitis. Further clinical
studies are needed to assess the role of coinfections in BMT
patients affected by HC.
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DETECTION AND QUANTITATIVE CANDIDA LOAD MONITORING USING
MOLECULAR BEACON PROBE
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Background: Candida infections account for 70%-80% of inva-
sive fungal infections and are among the most common nosocomial
bloodstream infections in BMT patients. Hence rapid identiﬁca-
tion of these Candida species may facilitate optimal antifungal
therapy and patient management. However, current biochemical
and phenotypic methods performed on isolated yeast colonies may
require up to a week. Here we report a rapid and sensitive geno-
typic method for identifying 6 Candida species: the 4 most com-
monly encountered species (C. albicans, C. glabrata, C. parapsilosis,
and C. tropicalis) and 2 inherently antifungal-resistant species (C.
krusei and C. lusitaniae). Identiﬁcation of these Candida species was
achieved by a single real-time PCR reaction with a novel molecular
beacon ﬂuorescent-probe and melting curve analysis. Methods:
We have designed a primer set for a unique region of the multi-
copy 18s rRNA gene. This primer set can amplify all 6 Candida
species in real time PCR using a nonspeciﬁc dye, SYBR Green. We
have designed a novel molecular beacon probe that hybridizes to
the internal sequences and exploits the slight sequence variations
between the species. Thus each Candida species may be discrimi-
nated by melting temperature (Tm) analysis. The performance of
this newly developed assay was evaluated in clinical blood speci-
mens that were spiked with several different dilutions of each
Candida species. Results: We have developed a real-time quanti-
tative PCR assay based on real-time ﬂuorimetric quantiﬁcation of
PCR products and evaluated its clinical diagnostic utility in inva-
sive candidiasis. Results indicate that our newly developed assay
can detect and quantify as few as 100 Candida cells/mL of blood for
all 6 medically important Candida species. In addition to detection
and quantitation, our novel hybridization probe allows the use of
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